The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia
Abstract
OBJECTIVE: Dopamine D2 receptor occupancy measurements provide a valid predictor of antipsychotic response, extrapyramidal side effects, and elevation of prolactin levels. The new antipsychotics clozapine, risperidone, and olanzapine obtain antipsychotic response with few extrapyramidal side effects and little prolactin elevation. The purpose of this study was to compare the D2 and serotonin 5-HT2 receptor occupancies of these drugs in patients receiving multiple-dose, steady-state regimens. METHOD: Forty-four patients with schizophrenia (16 taking risperidone, 2-12 mg/day; 17 taking olanzapine, 5-60 mg/day; and 11 taking clozapine, 75-900 mg/day) had their D2 and 5-HT2 occupancies determined with the use of [11C]raclopride and [18F]setoperone, respectively, and positron emission tomography imaging. RESULTS: Clozapine showed a much lower D2 occupancy (16%-68%) than risperidone (63%-89%) and olanzapine (43%-89%). Risperidone and olanzapine gave equal D2 occupancies at doses of 5 and 20 mg/day, respectively. All three drugs showed greater 5-HT2 than D2 occupancy at all doses, although the difference was greatest for clozapine. CONCLUSIONS: Clozapine, at doses known to be effective in routine clinical settings, showed a D2 occupancy clearly lower than that of typical antipsychotics, while risperidone and olanzapine at their usual clinical doses gave the same level of D2 occupancy as low-dose typical antipsychotics. The results also suggest that some previous clinical comparisons of antipsychotics may have been confounded by different levels of D2 occupancy. Clinical comparisons of these drugs, matching for D2 occupancy, may provide a better measure of their true "atypicality" and will help in understanding the contribution of non-D2 receptors to antipsychotic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Deficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in Brain
Burt, D. R., Creese, I., & Snyder, S. H. (1977) · Science · doi:10.1126/science.847477 · Cited by 1,024
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Self-citationArvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 803
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Farde, L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150013003 · Cited by 530
Nordström, A.-L., Farde, L., Wiesel, F.-A., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370
Self-citationSerotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors
Pazos, A., Probst, A., & Palacios, J. M. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90327-7 · Cited by 355
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1444 · Cited by 339
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · PubMed · Cited by 322
Huang, M.-L., Peer, A. V., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, A. A. I., Zylicz, Z., Visscher, H. W., & Jonkman, J. H. G. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.146 · Cited by 316
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306
Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.7.905 · Cited by 258
High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.7.948 · Cited by 252
Kapur, S., Remington, G., Zipursky, R. B., Wilson, A. A., & Houle, S. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02037-j · Cited by 229
Self-citationVanderZwaag, C. J., McGee, M., McEvoy, J. P., Freudenreich, O., Wilson, W. H., & Cooper, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1579 · Cited by 193
Farde, L., Suhara, T., Karlsson, P., Hietala, J., Nakashima, Y., Halldin, C., & Nyberg, S. (1997) · Psychopharmacology · doi:10.1007/s002130050420 · Cited by 177
Farde, L., Nyberg, S., Oxenstierna, G., Nakashima, Y., Halldin, C., & ERICSSON, B. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00004 · Cited by 157
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
Nyberg, S., Farde, L., Halldin, C., Dahl, M., & Bertilsson, L. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.173 · Cited by 143
A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects
Nyberg, S. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00218-7 · Cited by 135
Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials
Bollini, P., Pampallona, S., Orza, M. J., Adams, M. E., & Chalmers, T. C. (1994) · Psychological Medicine · doi:10.1017/s003329170002729x · Cited by 129
Trichard, C., Martinot, M. P., Attar-Levy, D., Recasens, C., Monnet, F. P., & Martinot, J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.505 · Cited by 125
Pilowsky, L. S., Busatto, G. F., Taylor, M., Sharma, T., Sigmundsson, T., Costa, D. C., Ell, P. J., & Nohria, V. (1996) · Psychopharmacology · doi:10.1007/bf02245615 · Cited by 120
Baron, J., Martinot, J. L., Cambon, H., Boulenger, J.-P., Poirier, M. F., Caillard, V., Blin, J., Huret, J. D., Loc’h, C., & Maziere, B. (1989) · Psychopharmacology · doi:10.1007/bf00589893 · Cited by 119
Blin, J., Sette, G., Fiorelli, M., Blétry, O., Elghozi, J. L., Crouzel, C., & Baron, J. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01229.x · Cited by 107
Lewis, R., Kapur, S., Jones, C., DaSilva, J. N., Brown, G. M., Wilson, A. A., Houle, S., & Zipursky, R. B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.72 · Cited by 101
Self-citationBlin, J., Pappatà, S., Kiyosawa, M., Crouzel, C., & Baron, J. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90635-8 · Cited by 94
Kapur, S., Zipursky, R. B., Remington, G. J., Jones, C., McKay, G., & Houle, S. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1525 · Cited by 93
Self-citationLidow, M. S., & Goldman, P. S. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37099-5 · Cited by 86
A new framework for investigating antipsychotic action in humans: lessons from PET imaging
Kapur, S. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000327 · Cited by 78
Self-citationTowards More Effective Antipsychotic Treatment
Kane, J. M., & Freeman, H. L. (1994) · The British Journal of Psychiatry · doi:10.1192/s0007125000293173 · Cited by 53
The D2 Receptor Occupancy Profile of Loxapine Determined Using PET
Kapur, S., Zipursky, R. B., Jones, C., Remington, G. J., Wilson, A. A., DaSilva, J., & Houle, S. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00100-5 · Cited by 39
Self-citationPET measurement of neuroreceptor occupancy by typical and atypical neuroleptics.
Goyer, P. F., Berridge, M. S., Morris, E. D., Semple, W. E., Compton-Toth, B. A., Schulz, S. C., Wong, D. F., Miraldi, F. D., & Meltzer, H. Y. (1996) · PubMed · Cited by 37
Petit-Taboué, M.-C., Landeau, B., Osmont, A., Tillet, I., Barré, L., & Baron, J. (1996) · PubMed · Cited by 36
Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT
Schlegel, S., Schlösser, R. G. M., Hiemke, C., Nickel, O., Bockisch, A., & Hahn, K. M. (1996) · Psychopharmacology · doi:10.1007/bf02246671 · Cited by 33
Kapur, S., JONES, C., DaSilva, J. N., Wilson, A. A., & Houle, S. (1997) · Nuclear Medicine Communications · doi:10.1097/00006231-199705000-00002 · Cited by 30
Self-citationStriatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone
Kufferle, B., Brücke, T., Topitz-Schratzberger, A., Tauscher, J. T., Gößler, R., Vesely, C., Asenbaum, S., Podreka, I., & Kasper, S. F. (1996) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(96)02839-9 · Cited by 27
Hietala, J. A., Kuoppamäki, M., Någren, K., Lehikoinen, P., & Syvälahti, E. K. G. (1997) · Psychopharmacology · doi:10.1007/s002130050356 · Cited by 18
Cited by
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Self-citationKapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Metadata
- Authors
- Kapur, S., Zipursky, R. B., & Remington, G.
- Venue
- American Journal of Psychiatry
- Published
- 1999-02-01
- Volume
- 156
- Issue
- 2
- Pages
- 286-293
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2155342545
- Cited by
- 712
- References
- 45
- FWCI
- 31.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.